Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Blood Component Transfusion”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 253 records · Page 14Linked to original sources
PubMed2005

[Towards bacterial detection in labile blood products].

Bacterial contamination of blood components represents today the highest infectious risk in blood transfusion, the risk is particularly high when it affects platelet concentrates. The prevention methods developed over the past ten years (donor selection, phlebotomy site preparation, first 30 ml diversion, systematic leuko-reduction...) which aimed at limiting the introduction of bacteria in donations and bacterial proliferation, has reduced the risk of transfusion reaction due to the bacterial contamination. Improving strategies for reducing the risks of bacterial contamination is one of the priorities of the French National Blood Transfusion Service (l'Etablissement français du sang - EFS). It is essential to improve existent prevention methods and develop the implication of all the actors (from donation to transfusion) involved in the prevention of this risk. Bacterial detection or pathogens inactivation are now available and are able to reduce (for detection) or prevent (for inactivation) the occurrence of reaction due to bacterial contamination of PC. Up to now, the choice is in favour of bacterial detection. Three methods (BacT/Alert, BioMerieux; eBDS, Pall; ScanSystem, Hemosystem) of detection of bacterial contamination in PC can be generalised now. Adaptations, need for their implementation are acceptable, especially concerning PC availability.

Automation↗
PubMed2004

Leucodepletion leads to component-like storage stability of whole blood--suggesting its homologous use?

BACKGROUND AND OBJECTIVES: Leucodepleted whole blood (LWB) is already widely used for autologous donations and could also be appropriate for certain instances of allogeneic transfusion provided that storage quality can be preserved at component-like levels. MATERIALS AND METHODS: Sixteen units of whole blood (WB), donated by healthy volunteers into CPDA-1 according to German guidelines, were leucofiltered prestorage and stored for up to 49 days. Unfiltered WB in CPDA-1 (UFWB, n=16) and filtered red blood cells in SAGM (RCC, n=14) served as controls. Several haematological, biochemical and coagulatory quality parameters were determined at designated time-points during storage. RESULTS: Apart from significant differences (P<0.05) in haematocrit (56.2+/-3.6 vs. 37.9+/-3.9%), and in the plasma concentrations of free haemoglobin (93.1+/-37.8 vs. 57.8+/-24.3 g/dl), K+ (38.9+/-5.3 vs. 31.5+/-4.3 mm) and ATP (2.7+/-0.2 vs. 1.6+/-0.4 micromol/g haemoglobin), with higher levels detected in RCC, no remarkable differences (P>0.05) were observed regarding haemolysis (0.23+/-0.07% vs. 0.31+/-0.13) and pH value (6.63+/-0.03 vs. 6.62+/-0.02) between RCC and LWB at the end of storage. Lack of leucodepletion manifested in significantly (P<0.05) higher rates of haemolysis (0.44+/-0.21%), free haemoglobin (89.6+/-43.5 g/dl) and lower pH values (6.56+/-0.04). During 42 days of LWB storage, sufficient amounts (% of the initial mean value) were observed with stable (factor XI, 97.5+/-15.0) and labile (factor V, 92.9+/-18.0; factor VIII, 69.2+/-17.1) clotting factors and inhibitors (antithrombin III 88.9+/-9.5), without any signs of activated coagulation. CONCLUSIONS: Our data indicate that the quality of LWB is comparable to that of components during 42 days of storage. Thus, LWB could be an interesting option for using to facilitate and economize the blood supply, especially for surgical or trauma patients.

Blood Coagulation Factors↗
PubMed1998

Transfusion-transmissible infections.

Infectious agents, including viruses, bacteria, and parasites, can be transmitted by human blood products. Of major importance are viruses such as human immunodeficiency virus types 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), and human T-cell lymphotropic virus types I and II (HTLV-I/II). Also, other viruses such as cytomegalovirus, Epstein-Barr virus, human parvovirus B19, and hepatitis A and G viruses can be transmitted by blood products. Various methods are used to prevent transmission of blood-borne agents to recipients, such as donor selection, testing donated blood for various infectious agents, and viral inactivation of plasma derivatives. With all these precautionary measures, the estimated risk for infection by screened blood components in Europe and the United States is approximately 1 in 50,000 to 1.6 million (for HBV, HCV, and HIV-1/2) transfused blood components. In the future, the safety of blood components may be increased by testing donated blood by nucleic acid amplification techniques and by photochemical decontamination of cellular blood components.

Bacterial Infections↗
PubMed2003

Thrombelastography. Present and future perspectives in clinical practice.

RESULTS: Thrombelastography (TEG) is a method for evaluating the viscoelastic properties of the blood clot, from its formation to its lysis. All major surgeries may be associated with massive blood loss, with blood component transfusion therapy often becoming mandatory. The clinician's goal is thus to optimize and possibly minimize blood components usage. To this end, TEG allows for a qualitative and dynamic analysis of the specific blood clotting process, from clot formation through its lysis, highlighting alterations at every single step in the cascade. With TEG is thus possible to know if bleeding is due to a failure to provide adequate surgical hemostasis, if there is platelet dysfunction, or to detect anomalies in coagulation proteases or their inhibitors, or if the blood loss is associated to early, excessive fibrinolysis. The theoretical advantages of TEG are the ease of performing the test, the fast sample reading times (now 30 minutes) and the informative

Blood Coagulation↗
PubMed1990

Blood transfusion and surgery: the effect on growth of a syngeneic sarcoma.

The effects of blood transfusion, blood components, and surgical trauma on the growth of an experimental sarcoma have been examined. Recipient animals were inbred adult female WAB rats, which received allogeneic transfusions from inbred adult female PVG rats, syngeneic blood from inbred colony-mates, or saline infusions. Small volume transfusions (1-4 ml) of whole blood had no effect on tumour growth, but growth of the MC7 sarcoma was significantly enhanced following allogeneic transfusions of 5 ml whole blood, or when 4 ml was combined with sham laparotomy. Maximal enhancement of tumour growth occurred when 4 ml transfusions of allogeneic washed cells were given, but allogeneic plasma was also able, to a lesser degree, to enhance tumour growth. These data confirm that blood transfusion may enhance growth of the MC7 sarcoma, that the effect may be dose dependent, and synergistic with the immunosuppression of surgery. Many components of an allogeneic transfusion may be responsible for this effect.

Animals↗
PubMed1992

Canine blood transfusions.

Although the technique of transfusing blood from one dog to another has been known for centuries, transfusion is not easily accomplished in clinical veterinary medicine. There is a lack of blood typing reagents, suitable donors, and commercial blood banks. This situation is beginning to change, and this article focuses on practical and accessible transfusion methods for dogs. Also discussed are recommendations regarding the type of blood product to be used in specific situations, routes of administration for blood products, and complications of blood transfusion.

Animals↗
PubMed1997

[Important points concerning quality control of blood products under the product liability law].

Two years have passed since the product liability(PL) law took effect in our country on July 1, 1995. At the start, we were uneasy about such things as an increase in lawsuits, the rise of medical care costs and the concealment of medical information. However, no-one has brought an action concerning blood products so far under the PL law. In terms of quality control of blood products, regular inspection of various instruments, reagents and manuals is the fundamental rule. Moreover, in order to ensure blood products of good quality, it is very important to select blood donors on the basis of physical examination and questionnaires on their medical condition, not to mention a range of screening tests to detect viral and bacterial infection. Since the first HIV infection through blood derived from an HIV-seronegative donor was reported in our country, it is especially desirable to improve measures for detecting HIV in window period blood for HIV antibody. There is also a problem concerning the irradiation of blood products to prevent PT-GVHD. We expect the PL law to provide a higher degree of safety of blood transfusion; however, it is also necessary to make proper use of blood products and to take the right measures in the event of adverse transfusion reaction, so as to raise the safety of blood transfusion.

Blood Component Transfusion↗
PubMed1993

Transfusion therapy: improved patient care and resource utilization.

Improving the quality of medical care while reducing costs is one of the major challenges facing the health care system in the United States. At a 1020-bed, tertiary-care, teaching hospital, the Transfusion Committee modified transfusion practice by establishing new transfusion guidelines based upon national standards rather than local practices and by implementing educational and monitoring systems. Over a 3-year period, the number of transfusions decreased, the types of transfused components changed, and the waste due to unused components decreased. From the baseline of Fiscal Year (FY) 1989 (89), the number of exposures to components from allogeneic blood donors for the patient population decreased by 11,015 in FY 90, 14,067 in FY 91, and 16,990 in FY 92, thereby decreasing the risk of transfusion-transmitted disease, transfusion reaction, and alloimmunization. As compared to costs in FY 89, the altered transfusion practices resulted in cost savings of $376,269 in FY 90, $566,375 in FY 91, and $684,704 in FY 92. Over the 3-year period, exposures to components from allogeneic blood donors for the patient population were reduced by 42,072, and the total cost savings was $1,627,348. The methodology and results should be reproducible at other hospitals.

Blood Component Transfusion↗
PubMed1993

The safe blood components for a hemophilia patient: a case report.

This study comments on safe blood components prepared for a 6 year old boy with hemophilia A (F VIII:C 1.8%). He has required blood transfusion since 10 months of age and started home therapy since 3 years of age. The utilized blood components were fresh dry plasma (FDP) prepared from 8-10 selected donors who were in good health and had no risk of blood-transmitted diseases. They were parents, relatives and friends with the age ranging from 30-45 years old. The FDP would be used after the donors had at least two subsequent negative tests for anti-HIV. In addition, cryoprecipitate collected from parents by plasmapheresis was started in 1990. Twelve to fifteen bags of cryoprecipitate were collected each plasmapheresis. The blood components prepared from the selected donors is an additional management to obtain the better quality of blood. Moreover, the role of parents taking the major responsibility in the recruitment of donors will minimize the shortage of blood donors.

Blood Component Transfusion↗
PubMed2001

Evaluation of a reporting system for bacterial contamination of blood components in the United States.

BACKGROUND: The transfusion of blood components contaminated with bacteria may have serious clinical consequences, but few data are available on the incidence of these events. A national effort to assess the frequency of blood component bacterial contamination associated with transfusion reaction (the BaCon Study) was initiated to better estimate their occurrence. STUDY DESIGN AND METHODS: Standard reporting criteria, data collection forms, and a standardized reporting protocol were developed in collaboration with the American Red Cross, AABB, and the Department of Defense. Episodes reported to the BaCon Study were compared with those reported to the FDA's national reporting systems to estimate the extent to which all serious reactions associated with bacterial contamination were captured. RESULTS: During the first 2 years, 38 episodes meeting study criteria were reported; 21 were laboratory-confirmed. The estimated proportion of episodes reported to the BaCon Study (i.e., completeness of coverage) was lower than that reported to the FDA during the same period (0.33 vs. 0.68), but the positive predictive value was higher (0.66 vs.0.28). CONCLUSION: Despite the complexity of obtaining reports from a large number of United States hospitals and transfusion centers, the feasibility and usefulness of the BaCon Study were shown. This study was the only national study in the United States to monitor adverse clinical events associated with bacterial contamination of blood components. By building on hospital-based reporting of transfusion-related adverse events, the BaCon Study serves as a model for the study of other complications associated with blood and blood components.

Bacterial Infections↗